Patents by Inventor Kai Dallmeier
Kai Dallmeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406889Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.Type: ApplicationFiled: May 5, 2023Publication date: December 21, 2023Applicant: Katholieke Universiteit LeuvenInventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
-
Publication number: 20230241201Abstract: The invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding the S1 and S2 subunits of a coronavirus Spike protein is located, such that a chimeric virus is expressed.Type: ApplicationFiled: March 1, 2021Publication date: August 3, 2023Inventors: Kai DALLMEIER, Johan NEYTS, Lorena SANCHEZ FELIPE, Hendrik, Jan THIBAUT, Dominique VAN LOOVEREN, Thomas VERCRUYSSE
-
Patent number: 11680084Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.Type: GrantFiled: October 5, 2018Date of Patent: June 20, 2023Assignee: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
-
Publication number: 20230183718Abstract: Provided herein are methods for the production of a vector with a size of at least 16 kb from bacterial cells comprising the consecutive steps of a) obtaining bacterial cells comprising a vector with a size of at least 16 kb, comprising an inducible origin of replication, b) inoculating culture medium with the bacterial cells comprising the vector, c) culturing the bacterial cells in the culture medium, d) adding one or more inducers of said inducible origin of replication to the culture medium when the bacterial culture has reached an optical density at 600 nm (OD600) of at least 20, e) further culturing the bacterial cells in the culture medium, f) optionally separating the bacterial cells from the culture medium, and g) recovering the plasmid from the bacterial cells. Also provided herein are vectors with a size of at least 16 kb comprising an inducible origin of replication for use in such methods.Type: ApplicationFiled: September 25, 2020Publication date: June 15, 2023Applicant: Katholieke Universiteit LeuvenInventors: Melody Janssen, Joeri Auwerx, Kai Dallmeier, Nicolas Ongenae, Cédric Vansalen, Nesya Goris
-
Patent number: 11566025Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: February 24, 2020Date of Patent: January 31, 2023Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
-
Publication number: 20220402976Abstract: The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.Type: ApplicationFiled: September 4, 2020Publication date: December 22, 2022Inventors: Kai DALLMEIER, Lorena SANCHEZ FELIPE, Viktor LEMMENS, Johan NEYTS
-
Publication number: 20220378903Abstract: The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order:—a further signal peptide of a Flavivirus NS1 protein,—an arenavirus Glycoprotein protein lacking the N terminal signal sequence and the GP2 transmembrane domain,—a TM1 and TM2 domain of a flaviviral E protein.Type: ApplicationFiled: September 11, 2020Publication date: December 1, 2022Inventors: Kai DALLMEIER, Viktor LEMMENS, Johan NEYTS, Lorena SANCHEZ FELIPE
-
Patent number: 11351240Abstract: The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.Type: GrantFiled: October 5, 2018Date of Patent: June 7, 2022Assignee: Katholieke Universiteit LeuvenInventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts, Michael Alexander Schmid
-
Publication number: 20220168412Abstract: A polynucleotide comprising the sequence of a live, infectious, attenuated Zika-Japanese encephalitis (JEV) chimeric virus wherein the nucleotide sequence encoding the prME protein of said Zika virus is replaced by a nucleotide sequence encoding the prME protein of a Japanese encephalitis virus, so that said prME protein of said Japanese encephalitis virus is expressed.Type: ApplicationFiled: April 10, 2020Publication date: June 2, 2022Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts
-
Publication number: 20220106321Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: November 30, 2021Publication date: April 7, 2022Applicant: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Patent number: 11279704Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: July 18, 2019Date of Patent: March 22, 2022Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Publication number: 20210353735Abstract: The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region.Type: ApplicationFiled: September 6, 2019Publication date: November 18, 2021Inventors: Kai Dallmeier, Niraj Mishra, Johan Neyts, Lorena Sanchez
-
Publication number: 20200331969Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.Type: ApplicationFiled: October 5, 2018Publication date: October 22, 2020Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
-
Publication number: 20200316187Abstract: The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.Type: ApplicationFiled: October 5, 2018Publication date: October 8, 2020Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts, Michael Alexander Schmid
-
Publication number: 20200223845Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: February 24, 2020Publication date: July 16, 2020Applicant: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
-
Patent number: 10633378Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: March 25, 2014Date of Patent: April 28, 2020Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
-
Patent number: 10550123Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: September 26, 2012Date of Patent: February 4, 2020Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Publication number: 20190337954Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: July 18, 2019Publication date: November 7, 2019Applicant: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Publication number: 20190111125Abstract: The invention relates to the use of a bacterial artificial chromosome (BAC) for the preparation of a vaccine, wherein the BAC comprises an inducible bacterial ori sequence for amplification of the BAC to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cDNA of an attenuated RNA virus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.Type: ApplicationFiled: September 17, 2018Publication date: April 18, 2019Inventors: Kai DALLMEIER, Johan NEYTS
-
Patent number: 10076564Abstract: The invention relates to the use of a bacterial artificial chromosome (BAC) for the preparation of a vaccine, wherein the BAC comprises an inducible bacterial ori sequence for amplification of the BAC to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cDNA of an attenuated RNA virus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.Type: GrantFiled: April 25, 2014Date of Patent: September 18, 2018Assignee: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Kai Dallmeier, Johan Neyts